Adc Therapeutics

ADC Therapeutics is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. They generate revenue primarily through the development and commercialization of their proprietary ADCs, which combine the targeting capabilities of antibodies with the cancer-killing ability of cytotoxic drugs. Founded in 2011 and headquartered in Lausanne, Switzerland, ADC Therapeutics has made significant strides, including the approval of their lead product ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma. Their innovative approach and strategic partnerships with leading pharmaceutical companies underscore their commitment to advancing cancer treatment.

Recent Posts by Adc Therapeutics

1-20 of 57